Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors
Financing led by OrbiMed with co-leads Novo Holdings and Jeito Capital Strengthened by substantial contributions from Frazier Life Sciences, Longitude Capital, RA Capital, and Catalio Capital, among others Proceeds will support development of first-in-class CLDN1…